AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00878748 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Effexor XR discontinue
Study NCT04366661 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: low dose CT
Description: Invited participants from institutes exposed to a high level of smoke pollution such as employees of Transport and Oil Ministries are inquired for their personal history of cigarette smoking then subjected to low dose CT
Study NCT04119674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug is Anlotinib.
Description: Anlotinib 8 mg/day (Chia-tai Tianqing Pharmaceutical Co., Ltd.) was given orally on days 1 to 14 per 3-week cycle for 2 cycles during concomitant therapy and maximally 8 cycles during adjuvant chemotherapy. One week after discontinuation of adjuvant chemotherapy, anlotinib 8 mg/day was given for maintenance .
Study NCT04119674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug is Temozolomide Capsule.
Description: Temozolomide 75 mg/m2/day was taken for maximally 49 days during concurrent chemoradiotherapy. Beginning 4 weeks after completion of concurrent chemoradiotherapy, patients received adjuvant temozolomide for 5 days every 28 days, first cycle 150 mg/m2/day and subsequent cycles 200 mg/m2/day for maximally 6 cycles .
Study NCT04119674 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy was initiated 4 to 6 weeks postoperatively.
Description: Radiotherapy was initiated 4 to 6 weeks postoperatively at a dose of 1.8-2.0 Grays (Gy) per fraction for 5 days per week for 6 weeks with a total dose of 54-60 Gy.
Study NCT03441087 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transvaginal ultrasound
Study NCT03441087 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hysteroscopy
Study NCT02732964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pandora Music
Description: Patients enrolled will be exposed to Pandora music for 30 minutes prior to their spinal anesthesia and cesarean delivery, and throughout their surgery.
Study NCT02732964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mozart Music
Description: Patients enrolled will be exposed to Mozart music for 30 minutes prior to their spinal anesthesia and cesarean delivery, and throughout their surgery.
Study NCT00638495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalfurafine Hydrochloride (TRK-820)
Description: TRK-820 2.5, 5 and 10 microg is to be administered orally once daily, after supper in principle, for 28 days.
Study NCT00638495 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is to be administered orally once daily, after supper in principle, for 28 days.
Study NCT03319134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active anodal HD-tDCS
Description: 1) active anodal HD-tDCS with memory task
Study NCT03319134 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham HD-tDCS
Description: 2) sham HD-tDCS with memory task
Study NCT03319134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active cathodal HD-tDCS
Description: 3) active cathodal HD-tDCS with memory task
Study NCT01930942 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: preoperative concurrent chemoradiation
Description: Radiation is given with 5000 cGy in 25 fractions (5 weeks). Concurrent chemotherapy consists of oxaliplatin (50 mg/m2 ) intravenously over 2 h on days 1, 8, 15, 22 and 29, and capecitabine (825 mg/m2 twice day) was given orally on each day of radiation.
Study NCT00128310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Study NCT00128310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Study NCT03245996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol Pill
Description: 50 or 100 mg of atenolol is administered to subjects in the second part of the study
Study NCT03245996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol Pill
Description: 5 mg of nebivolol is administered to subjects in the second part of the study
Study NCT03245996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine Pill
Description: 5 or 7,5 mg of ivabradine is administered to subjects in the second part of the study
Study NCT04474691 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional articulation treatment
Description: Traditional articulation treatment involves providing auditory models and verbal descriptions of correct articulator placement, then cueing repetitive motor practice. Images and diagrams of the vocal tract can be used as visual aids; however, no real-time visual display of articulatory or acoustic information will be made available. Knowledge of performance feedback could describe either the desired articulator placement or the auditory quality of the target sound.
Study NCT04474691 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual-acoustic biofeedback
Description: In visual-acoustic biofeedback treatment, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum generated by the staRt app. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3. Knowledge of performance feedback will typically involve reference to the location of the third peak or 'bump' on the visual display.
Study NCT02105987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ongoing cART regimen
Description: Stable cART regimens including boosted PI (or ATV unboosted) + 2 NRTIs; NNRTI + 2 NRTIs, or INI (RAL or EVG)+ 2 NRTIs
Study NCT04272788 — intervention group
Intervention type: DRUG
Intervention: Infliximab
Description: The CD patients at initial active stage without treatment of glucocorticoids, immunosuppressants and biological agents are included in the study when the decision to treat with Infliximab is already made. This study is observational, and all treatment and clinical follow-up are according to national guidelines.
Study NCT02419534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol
Description: Laxative to treat constipation
Study NCT02419534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol with Diltiazem
Description: Laxative and topical calcium channel blocker
Study NCT04495829 — intervention group
Intervention type: DEVICE
Intervention: Phorcides Analytical Engine
Description: Surgery planning using the Phorcides analytical engine.
Study NCT02212314 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Response Inhibition Training
Description: Computerized response inhibition training will be delivered via the Internet for 10 individual sessions.
Study NCT03715920 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical currents
Description: The training was planned as HVPG current for the the first group (n = 16), as Russian current for the second group (n = 15) and as isometric strengthening for the third group (n = 15). All treatments were performed under physiotherapist supervision for a total of 15 sessions for 3 days a week for 5 weeks.
Study NCT03715920 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Electrical currents
Description: The training was planned as HVPG current for the the first group (n = 16), as Russian current for the second group (n = 15) and as isometric strengthening for the third group (n = 15). All treatments were performed under physiotherapist supervision for a total of 15 sessions for 3 days a week for 5 weeks.
Study NCT03715920 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Electrical currents
Description: The training was planned as HVPG current for the the first group (n = 16), as Russian current for the second group (n = 15) and as isometric strengthening for the third group (n = 15). All treatments were performed under physiotherapist supervision for a total of 15 sessions for 3 days a week for 5 weeks.
Study NCT02144714 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SB5
Study NCT02144714 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB5
Study NCT02144714 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EU sourced Humira®
Study NCT02144714 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU sourced Humira®
Study NCT02144714 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US sourced Humira®
Study NCT03852654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: Subjects with biopsy proven prostate cancer, no prior local therapy, and:~PSA ≥ 10 ng/dl, or Gleason Sum ≥ 4+3, or clinical stage ≥cT2c Staging by 99mTc-MDP or NaF PET bone scan, and Diagnostic CT (pelvis) or MRI will undergo 18F DCFPyL PET CT scan.
Study NCT04163003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Approaches for Promoting Adolescent Sleep (TAPAS)
Description: The targeted intervention is a three part sleep program, involving a 2- minute psychoeducation video, an in-person session with a clinician focusing on sleep, and web-based goal setting related to sleep behaviors. Intervention approaches to promoting adolescent sleep and reducing insufficient sleep use a motivational interviewing style, rooted in cognitive-behavioral strategies for improving sleep.
Study NCT04163003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Monitoring Only
Description: Participants will monitor sleep with sleep diary, but they will not receive feedback or any other information on to sleep.
Study NCT03743415 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Handbook
Description: see arm/group descriptions
Study NCT03743415 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TIP-C plus Handbook
Description: see arm/group descriptions
Study NCT00128310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT04678752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight management care path
Description: * Documentation and data capture built in the Electronic Health Record~* Clinical data support that suggests weight loss approach(es)~* Tracking of weight loss progress and weight loss maintenance during patient visits to guide the patient-clinician conversation~* Diagnosis and billing in EHR automatically adds the diagnosis of overweight or obesity and links the most common weight-related co-morbidities to ensure adequate provider reimbursement~* Evidence-based online training on weight management for clinicians~* Practice quality improvement and training for use of PATHWEIGH for weight-prioritized visits through practice coaches/facilitators~* Consultation support by practice facilitators with implementing PATHWEIGH and by obesity providers for clinicians with creating patient treatment plans
Study NCT04678752 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Within primary care the option to select Obesity brief HPI, this is a brief historical intake of a patient's weight - when either they or their clinician decides to have a weight-prioritized visit. It is intended to initiate a discussion regarding potential strategies for weight loss (often eat less, exercise more). The provider has the discretion to augment or add support as they see fit.
Study NCT03226743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: collaborative and stepped care model
Description: Including elements:~* collaborative and stepped care of patients with mental disorders~* treatment in a multiprofessional network consisting of primary care physicians, psychologists, psychiatrists and inpatient facilities~* initial training of participating health care providers~* formalized and standardized screening procedure for early recognition of depressive, anxiety, somatoform and alcohol abuse disorders~* formalized ICD-diagnostics~* guideline-oriented treatment recommendations~* bibliotherapy or internet-based self-help for patient with mild to moderate disorders~* online referral platform~* case management for patients with severe disorders~* systematic and regular monitoring~* regular quality circles for participating health care providers
Study NCT03897673 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Early Iron
Description: iron syrup for the first three months (84 days) and placebo syrup for the fourth month
Study NCT03897673 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Delayed Iron
Description: placebo syrup for the first month (28 days) and iron syrup for the second, third, and fourth months
Study NCT00801216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose sequential chemotherapy and autologous transplant
Description: Two courses of methotrexate 3.5 g/mq day 1 and cytarabine 2 g/mq twice a day, for two days, Rituximab 375 mg/mq days 3 \& 11 and Intrathecal liposomal cytarabine 50 mg day 6(Phase I) followed in case of response by cyclophosphamide 7 g/mq plus Rituximab 375 mg/mq and Intrathecal liposomal cytarabine 50 mg Leukapheresis A and cryopreservation (Phase II), Cytarabine 2 g/mq twice a day for 4 days, Rituximab 375 mg/m2 and Reinfusion of stem cells (Phase III), etoposide 2 g/mq, Intrathecal liposomal cytarabine 50 mg (Phase IV) and high-dose Thiotepa-BCNU supported by autologous stem cell transplant (Phase V), and whole-brain radiotherapy in patients who do not achieve a complete remission after chemotherapy (Phase VI)
Study NCT04418258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capillary Endoscopy Aspiration Catheter
Description: Small intestinal fluid will be suctioned with using a capillary endoscopy aspiration catheter\[#CSL2182; Hobbs Medical,Inc. Connecticut, US\] during upper endoscopy
Study NCT04418258 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy Aspiration Catheter
Description: Small intestinal fluid will be suctioned with using an endoscopy aspiration catheter\[#2182; Hobbs Medical,Inc. Connecticut, US\] during upper endoscopy
Study NCT06726967 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: vitamin D 25(OH)D
Description: Thyroid functions (thyroid-stimulating hormone (TSH), serbest triiodothyronine (fT3), serbest thyroxine (fT4)); Thyroid antibodies (Anti-thyroid peroxidase (anti-TPO), anti-thyroglobulin (anti-TG))
Study NCT06727175 — intervention group
Intervention type: BEHAVIORAL
Intervention: non-invasive neuromodulation therapy
Description: Patients with subjective tinnitus were treated using non-invasive neuroregulation therapy. That is, to generate personalized, non-invasive acoustically stimulated neuroregulation regimens for six montns. Each participant was treated three times a day (morning, noon and bedtime) for 30 minutes each time.
Study NCT06727175 — intervention group
Intervention type: OTHER
Intervention: before any intervention
Description: before any intervention
Study NCT00964652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill walking training with additional body load
Description: The training program was divided into three phases (A1-B-A2):~treadmill training with additional body load (A1), control condition (conventional physical therapy) (B). and treadmill training with additional body load again (A2). Each phase lasted six weeks, totaling 18 weeks. Both evaluations and training were performed during on-phase of the medication cycle.
Study NCT04208438 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: BVI Device
Description: Non-Invasive measurement of jugular blood volume using Mespere BVI device
Study NCT04208438 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Point-of-Care Ultrasound
Description: Point-of-Care ultrasound of external and internal jugular veins
Study NCT01581060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WX-554
Description: Capsules of WX-554
Study NCT03301350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is a platinum compound alkylating agent which covalently binds to DNA; interferes with the function of DNA by producing interstrand DNA cross-links.
Study NCT03301350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel promotes microtubule assembly by enhancing the action of tubulin dimers, stabilizing existing microtubules, and inhibiting their disassembly, interfering with the late G2 mitotic phase, and inhibiting cell replication. In addition, the drug can distort mitotic spindles, resulting in the breakage of chromosomes. Paclitaxel may also suppress cell proliferation and modulate immune response.
Study NCT03301350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Inhibition of DNA and RNA synthesis by intercalation between DNA base pairs by inhibition of topoisomerase II and by steric obstruction. Doxorubicin intercalates at points of local uncoiling of the double helix. Although the exact mechanism is unclear, it appears that direct binding to DNA (intercalation) and inhibition of DNA repair (topoisomerase II inhibition) result in blockade of DNA and RNA synthesis and fragmentation of DNA. Doxorubicin is also a powerful iron chelator; the iron-doxorubicin complex can bind DNA and cell membranes and produce free radicals that immediately cleave the DNA and cell membranes.
Study NCT00819923 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: Intra-coronary stenting
Study NCT01639625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIGB300
Description: CIGB300: 15 mg, 35 mg and 70 mg All groups will receive CIGB-300 for local application.
Study NCT02956980 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood Plasmacytoid dendritic cells (pDCs) absolute number
Description: Two 7 ml tubes will be necessary to perform the functional assays as well as the quantification of blood pDCs absolute number. Functional assays will be performed on isolated PBMC by Ficoll procedure. Quantification of blood pDCs absolute number will be performed on whole blood. After written parental consent, blood sample will be performed on children participating to the study.
Study NCT03821519 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: donor-derived CIK cells
Description: Treatment plan will be based on three infusions of donor derived CIK cells given by 3 weeks intervals at increasing dose levels. No dose changes are allowed and the following planned dose levels will be administered to each patient enrolled: 5x106, 5x106 and 10x106 cells/Kg according to the dose escalating program
Study NCT05950529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental lozenge with the enzyme Polyphenol oxidase and green coffee extract
Description: Subjects will be instructed to allow their assigned lozenge to dissolve in the mouth while placed on the dorsal surface of the tongue. Subjects can suck on the lozenge and press the lozenge against the palate; however, the lozenge should not be moved around in the mouth or placed on the buccal mucosa. Subjects should avoid biting or chewing the lozenge and talking while dissolving the lozenge. After the lozenge has dissolved, the subject will be instructed to swallow the remaining solution.
Study NCT05950529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental lozenge with the enzyme Polyphenol oxidase, green coffee extract and flavor
Description: Subjects will be instructed to allow their assigned lozenge to dissolve in the mouth while placed on the dorsal surface of the tongue. Subjects can suck on the lozenge and press the lozenge against the palate; however, the lozenge should not be moved around in the mouth or placed on the buccal mucosa. Subjects should avoid biting or chewing the lozenge and talking while dissolving the lozenge. After the lozenge has dissolved, the subject will be instructed to swallow the remaining solution.
Study NCT05950529 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lozenge control (sorbitol only)
Description: Subjects will be instructed to allow their assigned lozenge to dissolve in the mouth while placed on the dorsal surface of the tongue. Subjects can suck on the lozenge and press the lozenge against the palate; however, the lozenge should not be moved around in the mouth or placed on the buccal mucosa. Subjects should avoid biting or chewing the lozenge and talking while dissolving the lozenge. After the lozenge has dissolved, the subject will be instructed to swallow the remaining solution.
Study NCT05950529 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No product
Description: no product
Study NCT01472666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High content of MC-SFA
Description: 12 weeks dietary intervention
Study NCT01472666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey
Description: 12 weeks dietary intervention
Study NCT01472666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low content of MC-SFA
Description: 12 weeks dietary intervention
Study NCT01472666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Casein
Description: 12 weeks dietary intervention
Study NCT00690573 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab administered subcutaneously every other week, with dosage determined by body weight at study entry (20 mg for children weighing less than 30 kg, 40 mg for children weighing 30 kg or more).
Study NCT04314115 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: Brief intervention in mindfulness, of individual type, of four sessions of sixty minutes per week, in addition to individual tasks, according to protocol of brief intervention in developed mindfulness.